Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Mantle-Cell × parsaclisib × Clear all

Phase

Phase 1 2 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Primary Myelofibrosis 1 Myeloproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 23 Cyclophosphamide 12 ibrutinib 8 Vincristine 8 Prednisone 8 Doxorubicin 8 Bendamustine Hydrochloride 8 Radiotherapy 7 Peripheral Blood Stem Cell Transplantation 5 Filgrastim 5 zanubrutinib 4 Lenalidomide 4 Cyclosporine 4 Mycophenolic Acid 3 Interferon-alpha 3 Cyclosporins 3 venetoclax 2 orelabrutinib 2 fludarabine phosphate 2 fludarabine 2 acalabrutinib 2 Whole-Body Irradiation 2 R-CHOP protocol 2 Psychiatric Rehabilitation 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Levofloxacin 2 Etoposide 2 Epoetin Alfa 2 Early Intervention, Educational 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04849715 2022-04-29

CITADEL-310

Incyte Corporation

Phase 3 Withdrawn

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡